This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


peer-reviewed publication


New approaches to treat the consequences of birth asphyxia

New approaches to treat the consequences of birth asphyxia
Individual box plots of percentage of brain area loss for experimental treatments and the pooled HI/saline group. In red is the data for all HI/Saline treated animals while green indicates the eight drugs which significant reduced brain area loss. Blue corresponds to the standard neuroprotective treatment (therapeutic hypothermia). Credit: Scientific Reports (2023). DOI: 10.1038/s41598-023-36653-9

Brain damage caused by oxygen deficiency at birth is one of the main causes of death in newborns worldwide. Using a small animal model, researchers from the University Hospital Bonn (UKB) and DZNE tested treatment with 25 different active agents. Seven substances proved to be more effective than the standard therapy of artificial cooling, and caffeine performed best. The results, published in the journal Scientific Reports, could pave the way for new treatment options for newborns.

Children, who experience oxygen deprivation during birth—a condition known as "birth asphyxia"—must be treated immediately, because the condition causes and poses an imminent life threat. In Germany, such issues are rare, but on a global level, birth asphyxia is one of the main causes of death among newborns. Globally, 1 million newborns die due to birth asphyxia each year.

To address this, so-called therapeutic hypothermia has been used for several years. This involves lowering the babies' body temperature to about 33°C for several days and then gradually raising it again. "The cooling slows down the metabolism and gives the brain the opportunity to regenerate. This increases the chances of survival and reduces the risk of late effects," explains Prof. Hemmen Sabir. The scientist and physician is a research group leader at DZNE and a senior physician in the Department of Neonatology and Pediatric Intensive Care at UKB.

"In high-income countries, the procedure is well established, however, about 40% of treated children do not benefit from it. And in low- and , the success rate is even much lower. The reasons for this are not entirely clear. However, they could be related to the fact that the newborns there have worse conditions than in due to the health status of their mothers and possibly unnoticed infections. In view of this, there is an urgent need for . That's where our study came in."

Study with 25 active agents

To date, hypothermia is the only established therapy for treating the consequences of oxygen shortage during childbirth. Drug alternatives have been tested worldwide—mostly in animal studies. However, the results of these investigations are difficult to compare to each other because they were done by different research groups and mostly in unequal settings. Therefore, Hemmen Sabir and his team aimed to test a range of compounds under identical conditions.

Based on studies performed by other research groups, they identified a total of 25 promising agents, which they then tested in a small animal model under oxygen deprivation. The animals were treated for up to six days: depending on the particular agent and its usage conditions, which were derived from previous studies. Of some agents, a first dose was administered shortly before oxygen deprivation.

"Transferred to humans, this means that these agents are given while the mother is still giving birth. This may happen, for example, in the case of obvious risks or complications," Sabir said. "However, only substances that can cross the placenta and therefore pass from the mother's bloodstream to the unborn child are suitable for this. We sort of simulated this situation in our study."

Caffeine was most effective

Seven days after oxygen deprivation, the animal brains were examined for damage. "Treatment with caffeine was the most effective, the loss of brain matter was lowest here and also significantly less than with hypothermic treatment," Sabir said. "Caffeine is known to have anti-inflammatory effects. Our study proves that caffeine is also extremely neuroprotective."

Six other agents also performed better than standard therapy. These comprise the , a medicine against gout, an anti-allergy drug and fish oil. The total of seven particularly effective agents includes both ones that were administered before —such as caffeine—and ones whose application occurred only afterwards.

Starting point for follow-up studies

"The advantage of drug treatment is that it does not require complex medical equipment. If caffeine does indeed turn out to be the drug of choice, we would also have an agent that is cheap and readily available. This form of therapy would be particularly well suited to developing countries. But certainly it could also be used in high-income nations if it is superior to hypothermic treatment," Sabir said.

Before testing on humans, however, additional studies in animal models would be necessary, and the mechanisms of action of the various substances would have to be investigated in greater detail in order to identify the best possible agent or any possible combinations. The Bonn researchers are in contact with international partners for this purpose. "If further laboratory studies produce positive results, I am confident that we can expect clinical trials in humans very shortly from now," Sabir said.

More information: Hemmen Sabir et al, Comparing the efficacy in reducing brain injury of different neuroprotective agents following neonatal hypoxia–ischemia in newborn rats: a multi-drug randomized controlled screening trial, Scientific Reports (2023). DOI: 10.1038/s41598-023-36653-9

Journal information: Scientific Reports
Provided by Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE)
Citation: New approaches to treat the consequences of birth asphyxia (2023, July 3) retrieved 17 June 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

World's first studies with bedside portable MRI in pediatric ECMO patients


Feedback to editors